In Germany, a leading manufacturer, Grüwald, which is known for its patent-free drugs had had its General Meeting on Tuesday, June 4, 2019 where the drugs used for therapeutic areas were discussed which are getting fame internationally as well. It is a Dermapharm Holding SE. The meeting was held in the Westin Grand Hotel, Munich. In the meeting, around 91.17% of the entire capital was shared and given representation. The agenda’s topics were favoured by approximately all.
In the general meeting that is held yearly, the Management Board reported in detail regarding the operational development as well as strategic development. The Dermapharm Holding SE meeting discussed in detail about report of the previous year 2018 as well as of the initial quarter of 2019, Dermapharm was able to keep its success story as it was delivering in the last years by having a significant sales and earnings in this year too. At the same time, the Management Board gave an outlook on the future strategy and the current fiscal year 2019.
In the Annual General Meeting in the last year of 2018, the Management Board and Supervisory Board got discharged by a high number of majorities. The proposal of the Management Board was followed by the General Meeting and resolved to distribute a dividend of EUR 0.77 per dividend-bearing share. The fiscal year 2019’s auditor was appointed. The new auditors which were appointed were Warth along with Klein Grant Thornton.
Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, takes stock: “In fiscal year 2018, we were able to successfully continue our growth course through the introduction of new products, further internationalization and acquisitions. With the dividend policy already formulated as part of the IPO, we allow our shareholders to participate in the company’s success. After the successful start in 2019, we will continue to consistently implement our strategy in order to grow profitably for the benefit of our shareholders.”